Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
March 21 2024 - 11:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: March 21, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
Exhibit No.
|
Description
of Exhibit
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Indivior PLC
|
Date: March 21,
2024
|
/s/
Kathryn Hudson
|
|
Name:
Kathryn Hudson
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior PLC
Appointment of Independent Non-Executive Director
Slough, UK, and Richmond, VA, March 21, 2024 -
The Board of Indivior PLC (LSE/Nasdaq: INDV) today announces the
appointment of David E. Wheadon, M.D. as an Independent
Non-Executive Director of the Company with effect from June 1,
2024. Dr. Wheadon is a health policy leader and physician
with more than three decades of global experience in the
pharmaceutical industry.
Graham Hetherington, Chair, commented:
'We are delighted to announce David's appointment as an Independent
Non-Executive Director. David has extensive experience in the
biopharmaceutical industry and expertise in global heath policy and
regulatory affairs, product quality and patient
safety. He
will be a tremendous asset as we continue to focus on our purpose
of pioneering life-transforming treatments for substance use
disorders, serious mental illness and accidental
overdose.'
Dr. Wheadon previously served as senior vice president of global
regulatory affairs, patient safety, and quality assurance at
AstraZeneca Plc from December 2014 to July 2019. Prior to that, he
was executive vice president, research and advocacy at Juvenile
Diabetes Research Foundation International Inc., from May 2013 to
December 2014, and senior vice president, scientific and regulatory
affairs at Pharmaceutical Research and Manufacturers of America
(PhRMA), from January 2009 to May 2013. Dr. Wheadon served as vice
president, global pharmaceutical regulatory and medical science,
and group vice president, global pharmaceutical regulatory affairs
at Abbott Laboratories from 2005 to 2009. Prior to Abbott
Laboratories, Dr. Wheadon held senior regulatory and clinical
development leadership positions at GlaxoSmithKline Plc and Eli
Lilly and Company.
Dr. Wheadon received his M.D. from Johns Hopkins University School
of Medicine and an A.B. in Biology from Harvard University.
He completed his postdoctoral training in Psychiatry at Tufts/New
England Medical Center in Boston, Massachusetts.
Dr. Wheadon is a Non-executive Independent Director of Sotera
Health Company (Nasdaq: SHC), Vaxart, Inc (Nasdaq: VXRT), and
ConnectiveRx. He also serves as a member of the Board of Trustees
of Mount Sinai Health System. Prior to its recent acquisition by
Bristol-Myers Squibb Company, Dr. Wheadon served as a Non-executive
Independent Director of Karuna Therapeutics, Inc (NASDAQ:
KRTX).
There is no further information to disclose in relation to Dr.
Wheadon's appointment in accordance with LR 9.6.13.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more
than 1,100 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Media Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
Indivior (PK) (USOTC:IZQVF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indivior (PK) (USOTC:IZQVF)
Historical Stock Chart
From Jul 2023 to Jul 2024